Correlation Between Enanta Pharmaceuticals and Novo Nordisk

Can any of the company-specific risk be diversified away by investing in both Enanta Pharmaceuticals and Novo Nordisk at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Enanta Pharmaceuticals and Novo Nordisk into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Enanta Pharmaceuticals and Novo Nordisk AS, you can compare the effects of market volatilities on Enanta Pharmaceuticals and Novo Nordisk and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Enanta Pharmaceuticals with a short position of Novo Nordisk. Check out your portfolio center. Please also check ongoing floating volatility patterns of Enanta Pharmaceuticals and Novo Nordisk.

Diversification Opportunities for Enanta Pharmaceuticals and Novo Nordisk

0.63

Correlation Coefficient

Enanta Pharmaceuticals  Novo Nordisk

Poor diversification

The 3 months correlation between Enanta and Novo is 0.63. Overlapping area represents the amount of risk that can be diversified away by holding Enanta Pharmaceuticals and Novo Nordisk AS in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Novo Nordisk AS and Enanta Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Enanta Pharmaceuticals are associated (or correlated) with Novo Nordisk. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Novo Nordisk AS has no effect on the direction of Enanta Pharmaceuticals i.e., Enanta Pharmaceuticals and Novo Nordisk go up and down completely randomly.

Pair Corralation between Enanta Pharmaceuticals and Novo Nordisk

Given the investment horizon of 90 days Enanta Pharmaceuticals is expected to under-perform the Novo Nordisk. In addition to that, Enanta Pharmaceuticals is 1.91 times more volatile than Novo Nordisk AS. It trades about -0.07 of its total potential returns per unit of risk. Novo Nordisk AS is currently generating about 0.06 per unit of volatility. If you would invest  6,528  in Novo Nordisk AS on September 5, 2024 and sell it today you would earn a total of  4,392  from holding Novo Nordisk AS or generate 67.28% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Enanta Pharmaceuticals  vs.  Novo Nordisk AS

Enanta Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Enanta Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite conflicting performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Novo Nordisk AS

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Novo Nordisk AS has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Enanta Pharmaceuticals and Novo Nordisk

The main advantage of trading using opposite Enanta Pharmaceuticals and Novo Nordisk positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Enanta Pharmaceuticals position performs unexpectedly, Novo Nordisk can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novo Nordisk will offset losses from the drop in Novo Nordisk's long position.

The idea behind Enanta Pharmaceuticals and Novo Nordisk AS pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.